EUVIMEDScopri EUVIMED
Crossref

Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC

Fatih Çöllü iD, Hayrettin Kadinşah iD, Zübeyde Öztel iD, Berrin Tuğrul iD, Erdal Balcan iD

Cell Biochemistry and Function · 2026-04 · 44 (4)

DOI: 10.1002/cbf.70201 ↗

At a glance

Journal article in Cell Biochemistry and Function, published online on 2026-03-27. Written by Fatih Çöllü and 4 co-authors. Institution: Molecular Biology Section, Department of Biology, Faculty of Engineering and Natural Sciences, Manisa Celal Bayar University, Yunusemre-Manisa, Turke…. Major MEDLINE topics: Doxorubicin, Drug Resistance, Neoplasm, Small Cell Lung Carcinoma, Lung Neoplasms. 37 references. Funded by: Manisa Celal Bayar University Scientific Research Projects Coordination Unit.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Multidrug resistance (MDR) remains a major challenge in small cell lung cancer (SCLC), limiting the efficacy of chemotherapeutics like doxorubicin. This study investigates whether silencing cellular prion protein (PrP), a known MDR‐associated molecule, can enhance doxorubicin‐induced cell death in Adriamycin‐resistant H69AR cells. Quantitative RT‐PCR and immunocytochemistry were used to assess the expression of PRNP , CD44 , BAX , and BECN1 under various treatment conditions, including doxorubicin exposure and PrP knockdown via siRNA. Autophagic activity was evaluated using monodansylcadaverine (MDC) staining. PrP knockdown significantly reduced PRNP expression and modulated CD44 mRNA levels, especially during doxorubicin co‐treatment. However, CD44 protein levels remained unchanged, suggesting post‐transcriptional regulation. BAX expression increased with doxorubicin and siRNA individually, but not in combination, indicating a PrP‐independent mechanism. BECN1 expression and Beclin‐1 protein levels were significantly elevated in all treatment groups, especially in siRNA/doxorubicin combination. MDC staining confirmed increased autophagic vacuole formation in this group, indicating activation of Beclin‐1‐mediated autophagy. In conclusion, PrP knockdown may sensitize resistant SCLC cells to doxorubicin and promote autophagy. These findings support PrP silencing as a promising strategy to reverse chemoresistance in SCLC.

Subjects

MeSH terms (MEDLINE)

DoxorubicinDrug Resistance, NeoplasmSmall Cell Lung CarcinomaLung NeoplasmsPrion ProteinsAntibiotics, AntineoplasticHumansRNA, Small InterferingBeclin-1AutophagyCell Line, TumorHyaluronan Receptors

Author keywords

BaxBeclin1CD44prion proteinsiRNAsmall cell lung cancer

Substances

DoxorubicinPrion ProteinsRNA, Small InterferingBeclin-1Antibiotics, AntineoplasticHyaluronan Receptors

Authors and institutions

  • Molecular Biology Section, Department of Biology, Faculty of Engineering and Natural Sciences, Manisa Celal Bayar University, Yunusemre-Manisa, Turkey.

ORCID profiles: Fatih Çöllü, Hayrettin Kadinşah, Zübeyde Öztel, Berrin Tuğrul, Erdal Balcan

Funding

  • Manisa Celal Bayar University Scientific Research Projects Coordination Unit

Cite

APA

Çöllü, F., Kadinşah, H., Öztel, Z., Tuğrul, B., & Balcan, E. (2026). Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. Cell Biochemistry and Function, 44(4). https://doi.org/10.1002/cbf.70201

Vancouver

Çöllü F, Kadinşah H, Öztel Z, Tuğrul B, Balcan E. Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. Cell Biochemistry and Function. 2026;44(4). doi:10.1002/cbf.70201

BibTeX
@article{ll2026,
  author = {Çöllü, Fatih and Kadinşah, Hayrettin and Öztel, Zübeyde and Tuğrul, Berrin and Balcan, Erdal},
  title = {Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC},
  journal = {Cell Biochemistry and Function},
  year = {2026},
  volume = {44},
  number = {4},
  doi = {10.1002/cbf.70201}
}
Start for free →